Sign up Australia
Proactive Investors - Run By Investors For Investors

Small-Cap Snapshot: Diagnostics company NeoGenomics reports better-than-expected earnings

The genetic testing company swung to a profit in its second quarter
Scientists in a lab
The researcher surpassed Wall Street earnings estimates

NeoGenomics Inc (NASDAQ:NEO) was a top gainer following better-than-expected second-quarter earnings. The diagnostics and research company reported adjusted earnings of US$0.05 per share compared with consensus estimates of US$0.04 EPS. The Florida-based company provides specialized cancer genetics testing. Shares jumped in pre-market hours and continued climbing about 1% to US$14.13 in morning trading.

Helix Energy Solutions Group Inc (NYSE:HLX) shares also received a post-earnings boost. The energy company turned a profit in its second quarter, reporting earnings of US$0.12 per share on revenue of US$17.8mln compared with an earnings loss of US$0.04 per share on a net loss of US$6.4mln. The Houston-based company offers offshore energy services in areas including Brazil and the Gulf of Mexico. Shares were up more than 4% to US$9.10.

READ: Biogen ups 2018 profit and revenue guidance after second-quarter earnings and revenue beat expectations

PGT Innovations Inc (NYSE:PGTI) is up on acquisition news. The company is purchasing fellow window manufacturer Western Window Systems in a US$360mln cash deal. The acquisition will help PGT to expand into the western and southwestern markets. Shares soared nearly 14% to US$24.17.

Noodles & Company (NASDAQ:NDLS) shares were in hot water following a proposed stock offering. The fast-casual restaurant chain is offering 2.5 million shares of its common stock for an undisclosed price. The company offers a range of noodle-based dishes from Italian classics to Pad Thai. Shares were down nearly 6% to US$11.32.

The Russell 2000 small-cap index was up slightly in Tuesday Morning trading.

View full NEO profile View Profile

NeoGenomics Timeline

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use